The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Rapid identification of drug-resistant BCR-ABL(+) leukemia.
Ronald J. Rieder
Employment or Leadership Position - BioSense Technologies
Stock Ownership - BioSense Technologies
Zhihui Zhao
Employment or Leadership Position - BioSense Technologies
Alex Chalmers
Employment or Leadership Position - BioSense Technologies
Richard M. Stone
Consultant or Advisory Role - ARIAD; Novartis; Teva
Research Funding - Novartis
Ilene Galinski
No relevant relationships to disclose